This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CMPI Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Checkmate Pharmaceuticals Stock (NASDAQ:CMPI) 30 days 90 days 365 days Advanced Chart Get CMPI alerts:Sign Up Key Stats Today's Range$10.50▼$10.5050-Day Range$10.37▼$10.5052-Week Range$2.00▼$10.50VolumeN/AAverage Volume142,261 shsMarket Capitalization$231.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read More Receive CMPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPI Stock News HeadlinesAxonis Therapeutics Announces $115 Million Series A FinancingOctober 31, 2024 | finance.yahoo.comvenBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesAugust 1, 2024 | finance.yahoo.comForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet.September 3 at 2:00 AM | Behind the Markets (Ad)University of Iowa Holden Comprehensive Cancer Center PresentsMay 26, 2022 | tmcnet.comUniversity of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingMay 26, 2022 | finance.yahoo.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates TVTY, ACC, SWCH, CMPIMay 18, 2022 | apnews.comACheckmate Pharmaceuticals GAAP EPS of -$0.73 beats by $0.02May 13, 2022 | seekingalpha.comCheckmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 13, 2022 | finance.yahoo.comSee More Headlines CMPI Stock Analysis - Frequently Asked Questions How were Checkmate Pharmaceuticals' earnings last quarter? Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.02. When did Checkmate Pharmaceuticals IPO? Checkmate Pharmaceuticals (CMPI) raised $75 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Checkmate Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Checkmate Pharmaceuticals investors own include Athenex (ATNX), KLX Energy Services (KLXE), TherapeuticsMD (TXMD), BioNTech (BNTX), Bolt Biotherapeutics (BOLT), Nabors Industries (NBR) and NGL Energy Partners (NGL). Company Calendar Last Earnings11/12/2021Today9/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CMPI CIK1651431 Webwww.checkmatepharma.com Phone617-682-3625FaxN/AEmployees28Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-83.92% Return on Assets-74.99% Debt Debt-to-Equity RatioN/A Current Ratio5.20 Quick Ratio5.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book4.20Miscellaneous Outstanding Shares22,038,000Free Float8,242,000Market Cap$231.40 million OptionableNot Optionable Beta-4.81 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CMPI) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkmate Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkmate Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
